Adenosine can signal immune cells to reduce activity; the IDO1 enzyme starts a separate route that breaks down tryptophan, an amino acid. Finding their components in a tumour does not prove immune suppression or drug benefit. An IDO1 blocker added to pembrolizumab did not improve melanoma outcomes in a phase 3 trial.
The adenosine route works outside cells. CD39 (ENTPD1) and CD73 (NT5E) are enzymes that help generate adenosine from extracellular ATP and ADP, and adenosine then acts on cell-surface receptors, including the A2A receptor on T cells. The enzymes can sit on immune cells, cancer cells or other tissue cells, so the source has to be measured and not assumed. The IDO route works inside a producing cell: IDO1 starts the breakdown of tryptophan along the kynurenine pathway. IDO is not an adenosine receptor and does not degrade ATP, so the two routes should not be merged into one 'suppressive axis'.
In plain words · IDO1 is an enzyme tumours use to burn up tryptophan, starving T cells and producing by-products that switch them off. Epacadostat blocked it but its programme ended in failure; the IO102-IO103 vaccine instead teaches T cells to attack the IDO1-expressing cells themselves.
Showing the target this term concerns: IDO1.
Shares IDO1, Epacadostat.
Shares Inflammation, Immune system.
Shares Inflammation, Immune system.
Shares Inflammation, Immune system.
Shares IDO1, Epacadostat, CD73 / adenosine axis, Tumour microenvironment (TME).
Shares IDO1, Tumour microenvironment (TME).
Shares Inflammation, Immune system.
Shares Immune system, Immune checkpoint, Tumour microenvironment (TME).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/